An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma

Cirino Botta, Sara Galimberti, Lucio Morabito, Cirino Botta, Massimo Martino, Anna Grazia Recchia, Mamdouh Skafi, Hamdi Al-Janazreh, Moien Atrash, Mohammed Abu-Rayyan, Ernesto Vigna, Giovanna Cutrona, Massimo Gentile, Fortunato Morabito

Risultato della ricerca: Articlepeer review

2 Citazioni (Scopus)

Abstract

Introduction: Regimens involving intensive immuno-chemotherapy, followed by high-dose therapy and autologous stem cell transplant represent the standard treatment for younger fit patients with mantle cell lymphoma (MCL). Targeted approaches (i.e. ibrutinib, bortezomib, and lenalidomide) represent the backbone of therapy for relapsed cases. Areas covered: Acalabrutinib is a novel small molecule with a butynamide moiety specifically designed to irreversibly inhibit Bruton tyrosine kinase (BTK), which is more potent and selective than ibrutinib. Relevant publications have been identified through literature searches using the terms ‘mantle cell lymphoma’ and ‘acalabrutinib’. Expert opinion: Acalabrutinib has been approved for the treatment of relapsed/refractory (RR) MCL patients. To date, clinical trials have reported some adverse effects such as cardiac toxicity or atrial fibrillation. Acalabrutinib in combination with other drugs, either in chemo-containing or chemo-free schedules, represent a valid option for MCL. However, none of the treatment schedules containing BTK inhibitors have been shown to be curative in MCL. Acalabrutinib may ultimately represent an option for patients who are ‘fit’ and exhibit well-controlled disease, which often characterizes only a limited ‘niche’ among MCL patients.
Lingua originaleEnglish
pagine (da-a)29-38
Numero di pagine10
RivistaExpert Opinion on Pharmacotherapy
Volume21
Stato di pubblicazionePublished - 2020

All Science Journal Classification (ASJC) codes

  • ???subjectarea.asjc.3000.3004???
  • ???subjectarea.asjc.2700.2736???

Fingerprint

Entra nei temi di ricerca di 'An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma'. Insieme formano una fingerprint unica.

Cita questo